Menu
Takes about two minutes.
Extensior is Abbott India's brand of semaglutide, developed and manufactured by Novo Nordisk and commercialised by Abbott under a partnership announced in February 2026 [3]. It is a second brand of Ozempic: the same original recombinant-DNA semaglutide, in the same FlexTouch pen, at 0.25 mg, 0.5 mg and 1 mg. Alongside lowering HbA1c and supporting weight reduction, it carries trial evidence for reducing cardiovascular and kidney events. This page explains that evidence, the risks, the cost and who it suits. Whether it is right for you is a decision for a doctor, not a checkout page.
What Extensior is
Extensior is not a generic. It is the original recombinant-DNA semaglutide, developed and manufactured by Novo Nordisk, and commercialised in India by Abbott under a partnership announced on 27 February 2026 [3]. It is described as a second brand of Ozempic, and it uses the same FlexTouch pen device at 0.25 mg, 0.5 mg and 1 mg weekly.
The distinction matters. Indian generic semaglutide products are separately manufactured versions that must demonstrate equivalence to the reference product. Extensior is the reference product, carrying the innovator's manufacturing process and the full global evidence package behind it: more than 44 clinical trials, over 10 real-world studies, and upwards of 49 million patient-years of use across semaglutide products [3].
It is a Schedule H, prescription-only medicine, indicated as an adjunct to diet and exercise in adults with type 2 diabetes. A Karespot doctor can assess whether it is clinically appropriate for you in a ₹599 online consultation.
Extensior belongs to the incretin family of medicines. Here is what it actually does in the body, without the jargon.
Extensior contains semaglutide, a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, one of the incretin hormones your gut releases after eating, closely enough to act like the real thing but last about a week instead of minutes.
It prompts insulin release only when blood sugar is high and suppresses glucagon at the same time. Because the effect is glucose-dependent, the risk of hypoglycaemia from semaglutide alone is low.
Your stomach empties more gradually and you feel full sooner, which flattens post-meal glucose spikes and usually produces weight reduction alongside the HbA1c improvement.
Extensior is manufactured by Novo Nordisk using the recombinant-DNA process behind the original semaglutide, and delivered in the same FlexTouch pen. Abbott commercialises it in India [3].
Doctor consultation
A 1:1 consultation with a specialist doctor
Takes about two minutes to book.
Extensior works by restoring a hormone signal your gut already produces. Here is the chain, from the first bite to a lower HbA1c.
Food reaching your small intestine triggers the release of GLP-1, a hormone your body already makes after every meal. In type 2 diabetes this incretin response is blunted. Natural GLP-1 breaks down within minutes; the semaglutide in Extensior sustains the same signal for about a week.
What happens
Semaglutide improves insulin secretion when glucose is high and suppresses glucagon, the hormone that raises blood sugar. Because both effects are glucose-dependent, they ease off as your blood sugar normalises, which is why hypoglycaemia risk from the medicine alone is low.
What happens
Your stomach empties more gradually, so sugar enters the blood as a trickle rather than a spike. GLP-1 also acts on the appetite centres of the brain, so intake tends to fall, which is why weight reduction usually accompanies the glycaemic benefit.
What happens
These benefits are established for semaglutide at the doses Extensior supplies. Which of them apply to you depends on your diagnosis and your cardiovascular and kidney status. Numbered references link to the sources at the end of this page.
Powerful glycaemic control in adults with type 2 diabetes, as an adjunct to diet and exercise [3][5].
In SUSTAIN-6, semaglutide cut major adverse cardiovascular events by about 26% over roughly two years in adults with type 2 diabetes at high cardiovascular risk [1].
In the FLOW trial, semaglutide 1 mg reduced major kidney events by about 24% in adults with type 2 diabetes and chronic kidney disease [2].
Weight loss is a well-established effect of semaglutide, and most people see it alongside the improvement in blood sugar [3].
These are outcome trials of semaglutide at the doses Extensior supplies, published in the New England Journal of Medicine. Each stat links to its source. They describe what the medicine achieved in the populations studied, alongside standard care. Averages are not promises: results vary with your starting point, dose, adherence and the rest of your treatment.
lower risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes at high cardiovascular risk.
SUSTAIN-6 · NEJM 2016 [1]lower risk of major kidney events on semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease, across 3,533 participants.
FLOW · NEJM 2024 [2]patient-years of use accumulated globally across semaglutide products, across more than 44 clinical trials and over 10 real-world studies.
Abbott India · February 2026 [3]Medical information verified by Dr. Prakrati Garg · Medical Content Author, Karespot · 29 August 2026
A simple form reviewed against clinical criteria. No payment needed to check.
Check your eligibilityTakes about 2 minutes · No obligation
Whether Extensior suits you depends on your glycaemic control, your cardiovascular and kidney risk, and the rest of your regimen. Meeting the criteria below is the starting point of a medical assessment, not a guarantee of a prescription.
The licensed indication: improving glycaemic control as an adjunct to diet and exercise, typically where existing therapy has not reached target [3][5].
The outcome data is strongest in adults with type 2 diabetes who also have established cardiovascular disease or chronic kidney disease [1][2].
Your doctor screens your medical history for contraindications (including pregnancy, type 1 diabetes, and a personal or family history of medullary thyroid carcinoma or MEN 2), reviews your existing medication for interaction and hypoglycaemia risk, and checks for a history of diabetic retinopathy before any prescription decision. If Extensior isn't right for you, we will tell you, and point you to what is. Meet our medical team.
Your next step
One call with an NMC-registered Internal Medicine doctor tells you whether semaglutide fits your situation, and which brand and dose make sense in your case.
These are the gastrointestinal side-effect rates reported for semaglutide at the 1 mg dose in the pooled SUSTAIN safety data, shown against placebo, because context matters [5]. They describe the molecule rather than any one brand, so they apply to Extensior and to every other semaglutide product at this dose. Most effects were mild to moderate, occurred mainly during dose escalation, and settled with time.
Rates are approximate, drawn from pooled semaglutide safety data in the prescribing information [5]; confirm against your pack insert. · Manufacturer information
Rare but serious risks (pancreatitis, gallbladder disease and severe allergic reactions) are screened for against your personal and family history before any prescription. One finding deserves specific mention: in SUSTAIN-6, diabetic retinopathy complications were more frequent on semaglutide than on placebo, thought to relate to the speed of glucose lowering in people with pre-existing retinopathy [1]. Tell your doctor if you have retinopathy, and report any sudden change in vision. Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, in type 1 diabetes, and in pregnancy.
Using Extensior
Extensior is supplied in the FlexTouch pre-filled pen and injected under the skin (subcutaneously) once a week, on the same day each week, into the abdomen or the thigh, or the upper arm if someone else is administering it [3]. It can be taken with or without food, and at any time of day. Rotate the site every week rather than injecting the same spot twice in a row.
The practical rules your Kare Team will walk you through on your first injection:
Where to inject: abdomen or thigh (upper arm if administered by someone else). Divide the area into four sections and use a different one each week, keeping each injection at least a finger-width from the last and 5 cm from the belly button.
Your prescribing doctor and Kare Team will demonstrate the injection technique before your first dose. If you also take insulin, never mix the two in one injection or use the same site at the same time. Never change your dose, timing or injection routine without speaking to your doctor first.
Extensior is never started at a treatment dose. The standard schedule begins at 0.25 mg once weekly for four weeks, moves to 0.5 mg, and then, only where further control is needed, to 1 mg [3][5]. Extensior is supplied in these three strengths. This is the typical plan; yours may look different, and your doctor may hold you at a lower dose if it is working.
The initiation dose: it lets your body adjust and is not intended to control blood sugar on its own.
The first therapeutic dose. Many people stay here if their HbA1c reaches target.
The highest strength Extensior supplies, used where further control is required. This is the dose studied in FLOW.
Extensior is listed at roughly ₹3,999 to ₹5,999 a month across its three strengths [4]. Abbott did not disclose pricing at the February 2026 launch announcement, and the figures below come from retail listings that appeared afterwards. Each FlexTouch pen covers about four weeks, and the cost rises with the strength. Extensior sits below the imported innovator brand and above the Indian generics.
| Strength (weekly) | Indicative monthly cost | Notes |
|---|---|---|
| 0.25 mgStarting dose · FlexTouch pen | from ~₹3,999 | Every course starts here, for the first 4 weeks, while your body adjusts. |
| 0.5 mgFirst therapeutic dose · FlexTouch pen | mid-range | Sits between the 0.25 mg and 1 mg strengths. Confirm the exact MRP with your pharmacy. |
| 1 mgHighest strength · FlexTouch pen | up to ~₹5,999 | The top of the published Extensior range, and the dose studied in the FLOW kidney trial [2]. |
| Full published rangeAll three strengths | ₹3,999–₹5,999/month | Retail listing for Extensior, Abbott India, across three variants [4]. |
| Indian generic semaglutideSame molecule, for comparison | from ~₹1,300–2,200 | DCGI-approved products from Sun Pharma, Eris, Alkem and Zydus. See our semaglutide page. |
These are indicative retail figures, not quotations, and the per-strength split within the published range is inferred from the usual pattern rather than separately confirmed. Prices vary by pharmacy and city, and the Indian semaglutide market has moved quickly through 2026. Verify the current price with your pharmacy before you budget. Extensior is a Schedule H medicine: your dose is decided by your doctor based on your HbA1c, your response and your tolerance, never by price, and dispensing requires a valid prescription. Start with a ₹599 doctor consultation to find out whether treatment is right for you at all.
Comparisons
Four questions patients ask us now that the same molecule is sold in India under more than twenty names.
Information verified by
It is the original. Extensior is developed and manufactured by Novo Nordisk using the recombinant-DNA process behind the innovator molecule, and commercialised in India by Abbott under a partnership announced on 27 February 2026 [3]. It is described as a second brand of Ozempic and uses the same FlexTouch pen.
An Indian generic, by contrast, is separately manufactured by another company and approved on the basis of demonstrated equivalence to the reference product. Both contain semaglutide. The difference is who made it and which manufacturing process and evidence package sits behind it.
Essentially the brand name and who sells it. Extensior is a second brand of Ozempic: the same molecule, made by the same manufacturer, in the same device, at the same 0.25 mg, 0.5 mg and 1 mg strengths [3].
The reason two brands exist is commercial reach. Abbott has a deep distribution network across Indian pharmacies and physicians, including beyond the regions Novo Nordisk currently serves directly, so the second brand widens availability [3].
Extensior sits deliberately in the middle: below the imported innovator brand, above the Indian generics, which start from roughly ₹1,300 a month.
What you are paying the difference for is the innovator's own manufacturing and the evidence package attached to it, including the cardiovascular and kidney outcome trials on this page and the accumulated real-world use. What the generics offer is the same molecule at a fraction of the cost, which matters over a treatment measured in years rather than months.
There is no universally correct answer. Cost is one of the biggest reasons people stop treatment early, and a medicine you cannot sustain is not the better medicine. Your doctor weighs your cardiovascular and kidney risk, your targets, the device you will use reliably, and what you can afford long term.
Switching between semaglutide products at the same strength is usually straightforward because the molecule is identical, and it is normally done at an equivalent dose. It should still be a decision your doctor makes and documents, because device technique differs between brands and formats.
Switching down from a higher-strength formulation needs more planning: if you are on 1.7 mg or 2.4 mg, Extensior's top strength is 1 mg, and that change has consequences for both appetite and glycaemic control. Speak to our Kare team before switching anything.
In India, semaglutide is prescribed by specialist doctors: internal medicine physicians and endocrinologists. It is a Schedule H medicine, and a pharmacy can dispense it solely against a valid prescription from a registered medical practitioner.
Specialists in adult medicine (MD, Internal Medicine), including the Karespot doctors who assess and prescribe for every patient on this programme.
Hormone and metabolism super-specialists (DM, Endocrinology), typically involved in complex diabetes or endocrine cases.
Treatment should never be started or changed on someone else's prescription or advice, because the dose interacts with the rest of your regimen and can cause hypoglycaemia alongside insulin or a sulfonylurea. No gym, wellness clinic or online seller can legitimately supply Extensior without a prescription. Every Karespot prescription is written by an NMC-registered Internal Medicine doctor after a full assessment. Meet our medical team.
Your doctors
Every Karespot patient is seen by an NMC-registered doctor with specific experience in metabolic medicine, listed with their State Medical Council. Your doctor stays involved from your first consultation to the end of your programme.
Use the arrows, swipe or scroll to meet all 3 prescribers
50% 25%; transform: scale(1.0);
NMC Registered Practitioner
MBBS, MD (Internal Medicine)
Professor of Medicine with deep clinical experience in diabetes and metabolic medicine. He treats type 2 diabetes, insulin resistance and obesity-related metabolic disorders through personalised, evidence-based plans.
Registration: Uttarakhand Medical Council Registered Practitioner: 3461
50% 25%; transform: scale(1.0);
NMC Registered Practitioner
MBBS, MD (Internal Medicine)
Internal medicine physician specialising in metabolic health, weight management, diabetes and lifestyle medicine. He treats root causes (insulin resistance, hormonal imbalance and inflammation) rather than symptoms alone.
Registration: Uttarakhand Medical Council Registered Practitioner: 10178
50% 25%; transform: scale(1.0);
NMC Registered Practitioner
MBBS, MD (Internal Medicine)
Internal medicine physician focused on hormonal and metabolic health. She has helped hundreds of patients manage PMOS (PCOS), thyroid dysfunction and insulin resistance with an empathy-led, evidence-based approach.
Registration: Uttarakhand Medical Council Registered Practitioner: 32876
Speak to a Karespot doctor today
Book in two minutes. A straight answer on eligibility on the same call, including a no, where treatment isn't right for you.
Book your consultation (₹599)About Extensior
Extensior is a GLP-1 receptor agonist containing semaglutide, indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It mimics glucagon-like peptide-1, a hormone your gut releases after eating to signal fullness, slow digestion and regulate insulin.
It is developed and manufactured by Novo Nordisk and commercialised in India by Abbott India Limited under a partnership announced in February 2026. It is a second brand of Ozempic, the most prescribed GLP-1 receptor agonist molecule globally, which has been on the market for close to a decade with more than 49 million patient-years of use across semaglutide products [3].
Strengths: 0.25 mg, 0.5 mg and 1 mg, once weekly
Device: FlexTouch pre-filled pen
Active Ingredient: Semaglutide (recombinant DNA origin)
Drug class: GLP-1 receptor agonist
Manufacturer: Novo Nordisk
Marketed in India by: Abbott India Limited
Storage: 2–8°C. Do not freeze
Extensior can be injected into the abdomen or thigh. Choose an injection area that feels most comfortable. Rotate the injection spot every week by splitting the selected area into four sections and using a different section each time. Place each new injection at least a finger-width away from the previous one, and if injecting into the abdomen, keep the injection at least 5 cm away from the belly button.
Support & safety
Information verified by
Before you proceed to checkout, please complete the eligibility check to confirm that you meet the basic criteria for the programme.
Once you move to payment, it means you've reviewed the eligibility requirements and would like to reserve your place in our limited-size programme. After payment, our clinical team will complete a medical review to confirm suitability.
If you are found ineligible during the medical review, we will refund your payment in full. Refunds are typically processed within 3–5 business days.
If you are found ineligible during the medical review, we will refund your payment in full. Refunds are typically processed within 3–5 business days.
In case you change your mind post consultation with the doctor, a nominal consultation fee of INR 500 will be charged and the balance amount will be refunded in 3–5 days.
These describe the molecule rather than any one brand. The most common, with approximate reported rates at the 1 mg dose against placebo [5]:
Also reported: indigestion and reflux, burping and gas, bloating, dizziness, fatigue, injection site reactions, and hypoglycaemia when combined with insulin or a sulfonylurea. Gastrointestinal effects usually appear or worsen around a dose increase, then settle.
The medical information on this page is written and verified by the Karespot clinical content team. It provides general information and is not a substitute for a consultation. Eligibility and treatment decisions are always made by your doctor. Meet our medical team.
Using Extensior · FAQ
Information verified by
Yes. Extensior is a Schedule H, prescription-only medicine and can only be dispensed against a valid prescription from a licensed medical doctor.
At Karespot, every patient is assessed by an NMC-registered doctor (MBBS, MD Internal Medicine) before any prescription is issued. If you are not clinically suitable, we will tell you, and refund you.
Semaglutide begins acting soon after the first injection, but the 0.25 mg starting dose is an initiation dose rather than a therapeutic one, so meaningful change follows the step up to 0.5 mg.
HbA1c reflects roughly three months of blood sugar, so your doctor will usually reassess it about twelve weeks after you reach a stable dose rather than judging progress from early readings alone.
Semaglutide has a half-life of about one week. After your final dose it can remain in the body for roughly five to seven weeks, with full clearance taking around eight to ten weeks depending on individual factors such as kidney function and general health. Its effects on appetite and blood sugar fade gradually rather than stopping abruptly.
Extensior should be kept in the fridge at 2°C to 8°C. It must not be frozen or exposed to direct light. Storage rules once a pen has been started differ from unopened storage, so follow the instructions in your pack insert, and speak to your Kare Team before travelling rather than improvising the cold chain.
Take your injection on the same day each week to keep levels steady. If you forget a dose:
Monitor your blood sugar more closely around a missed dose, and contact your doctor if readings are unusual.
Usually yes, and it is commonly added to an existing regimen. But the combination matters: taken alongside insulin or a sulfonylurea, semaglutide increases the risk of hypoglycaemia, and your doctor may reduce those doses when starting it.
Because semaglutide slows gastric emptying, it can also affect how quickly other oral medicines are absorbed. Give your doctor a complete list of everything you take, including supplements, before you start.
Effects fade as the medicine clears, and both appetite and blood sugar typically drift back toward where they were. We would rather tell you that honestly upfront.
Type 2 diabetes is a chronic, progressive condition, and semaglutide works while you take it. This is why Karespot pairs medication with dietician coaching, psychologist support and strength-based activity: what you build alongside treatment is what remains if the medicine ever stops.
Still have a question?
Speak to a Karespot doctor and get a clear answer about whether Extensior is right for you.
Check your eligibilityThe medical information on this page is written and verified by the Karespot clinical content team. It provides general information and is not a substitute for a consultation. Eligibility and treatment decisions are always made by your doctor. Meet our medical team.
Karespot does not sell Extensior from this page. If a doctor finds semaglutide clinically appropriate for you, it is prescribed and dispensed through a licensed partner pharmacy inside a supervised programme, with dietician, psychologist and coaching support around it.
Treatment is recommended only where clinically appropriate, and every cost is shown transparently before you commit.
Evidence
Every clinical claim and statistic on this page is traceable to one of the sources below (the numbered markers [1]–[5] through the page point here) and each reference links on to the original. Clinical statistics are reported as published. Pricing figures are drawn from retail listings rather than clinical evidence, and are labelled as indicative in the pricing section.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 2016;375:1834–1844.
Source for the cardiovascular outcome figure and for the diabetic retinopathy safety signal, in adults with type 2 diabetes at high cardiovascular risk.
Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine, 2024;391:109–121.
Source for the kidney outcome figures on semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease.
Abbott India. Press release: Abbott partners with Novo Nordisk India to launch Extensior, broadening access to semaglutide (Ozempic) for advanced diabetes management. 27 February 2026.
Source for the Abbott and Novo Nordisk partnership, the manufacturing and commercialisation arrangement, the licensed indication, the FlexTouch device, the 0.25 mg, 0.5 mg and 1 mg strengths, and the clinical trial and patient-year figures.
Tata 1mg. Semaglutide: brands, variants and retail prices in India.
Source for the Extensior retail price range across its three variants, and for comparison against other semaglutide brands available in India.
Novo Nordisk. Semaglutide injection: prescribing and product information.
Manufacturer of semaglutide; source for administration, injection technique, storage, the standard titration schedule, and the side-effect rates reported at these doses.
This page is for information only and is not a substitute for a medical consultation. Extensior is approved in India as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Treatment is recommended only where it is clinically appropriate for you, following an assessment by a registered medical practitioner. Any prescription-only treatment is provided solely under a valid prescription and active medical supervision, and all products are supplied in compliance with the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. Karespot is not affiliated with Abbott or Novo Nordisk and does not endorse any particular manufacturer or brand; product selection is a clinical decision made by your doctor. Individual results vary. Prices shown are indicative published figures at the time of review and are subject to change.
Ask us anything before you decide. A real person from the Karespot team will answer, not a bot.
We usually reply within a few hours
